Actuate Therapeutics, Inc. Common stock

ACTUNASDAQUSD
1.44 USD
0.04 (2.50%)🟢LIVE (AS OF 11:50 AM EDT)
🟢Market: OPEN

ACTU is currently priced at $1.44. Technical and fundamental signals converge bearishtechnicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jul 6, 2026.

Open?$1.37
High?$1.46
Low?$1.37
Prev. Close?$1.40
Volume?29.0K
Avg. Volume?173.7K
VWAP?$1.42
Rel. Volume?0.17x
Bid / Ask
Bid?$1.20 × 100
Ask?$1.64 × 100
Spread?$0.44
Midpoint?$1.42
Valuation & Ratios
Market Cap?33.5M
Shares Out?23.9M
Float?9.5M
Float %?40.3%
P/E Ratio?N/A
P/B Ratio?8.85
EPS?-$0.90
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Employees
12
Market Cap
36.4M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2024-08-13
Address
1751 RIVER RUN
FORT WORTH, TX 76107
Phone: 847-986-4190
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-3/3)
Medium-Term (Wave)? Bearish(-2/3)
Short-Term (Ripple)? Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
77
Short Sent.?
60
Piotroski F-Score?0/9Weak
Altman Z-Score?-28.83Distress
Confidence?38%Very Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?9.59%Elevated
Short Interest?915.4K
Days to Cover?4.4
Free Float9.5M
Avg Daily Volume206.0K
Settlement Date2026-06-15
Financial Health
Current Ratio?1.80Adequate
Quick Ratio?1.80Adequate
Cash Ratio?1.72Strong
Debt/Equity?0.01Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A
P/B?
Peers
100
S&P
21
8.85HIGH
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
S&P
97
-1.2CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
3
-569.1%WEAK
ROA?
S&P
3
-241.7%WEAK
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$25.4M
Fundamentals ratios updated end of day